


Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-187 (cancelled)

Claim 188 (new) A compound of the formula



or a pharmaceutically acceptable salt thereof wherein

R₁ is:

- AI
- (I) C₁-C₆ alkyl, unsubstituted or substituted with one, two or three C₁-C₃ alkyl, -F, -Cl, -Br, -I, -OH, -NH₂, -C≡N, -CF₃, or -N₃,
 - (II) -(CH₂)₁₋₂-S-CH₃,
 - (III) -CH₂-CH₂-S-CH₃,
 - (IV) -CH₂-(C₂-C₆ alkenyl) unsubstituted or substituted by one -F,
 - (V) -(CH₂)₀₋₃-(R₁-aryl) where R₁-aryl is phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetralinyl unsubstituted or independently substituted on the aryl ring with one or two of C₁-C₃ alkyl, -CF₃, -F, Cl, -Br, -I, C₁-C₃ alkoxy, -O-CF₃, -NH₂, -OH, or -C≡N;

R₂ is:

- (I) -H,
- (II) C₁-C₆ alkyl, or

(III) - (CH₂)₀₋₄-R₂₋₁ where R₂₋₁ is (C₃-C₆)cycloalkyl, R_{1-aryl} where R_{1-aryl} is optionally substituted with R₁₀₀, where R₁₀₀ is

- A¹
- (1) C₁-C₆ alkyl,
 - (2) -F, -Cl, -Br, or -I,
 - (3) -OH,
 - (4) -NO₂,
 - (5) -CO-OH,
 - (6) -C≡N,
 - (7) -CO-NR_{N-2}R_{N-3} where R_{N-2} and R_{N-3} are the same or different and are:
 - (a) -H,
 - (b) -C₁-C₆ alkyl unsubstituted or substituted with one -OH or -NH₂,
 - (c) -C₁-C₆ alkyl unsubstituted or substituted with one to three -F, -Cl, -Br, or -I,
 - (d) -C₃-C₇ cycloalkyl,
 - (e) -(C₁-C₂ alkyl)-(C₃-C₇ cycloalkyl),
 - (f) -(C₁-C₆ alkyl)-O-(C₁-C₃ alkyl),
 - (g) -C₁-C₆ alkenyl with one or two double bonds,
 - (h) -C₁-C₆ alkynyl with one or two triple bonds,
 - (i) -C₁-C₆ alkyl chain with one double bond and one triple bond,
 - (8) -CO-(C₃-C₁₂ alkyl),
 - (9) -CO-(C₃-C₆ cycloalkyl),
 - (11) -CO-R_{1-heterocycle} where R_{1-heterocycle} is morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydrothiophenyl,

where the R_1 -heterocycle group is bonded by any atom of the parent R_1 -heterocycle group substituted by hydrogen such that the new bond to the R_1 -heteroaryl group replaces the hydrogen atom and its bond, where heterocycle is unsubstituted or substituted with one or two

=O, C_1 - C_3 alkyl, $-CF_3$, $-F$, Cl , $-Br$, $-I$, C_1 - C_3 alkoxy, $-OCF_3$, $-NH_2$, $-OH$, or $-C\equiv N$,

- A1
- (12) $-CO-R_{N-4}$ where R_{N-4} is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two C_1 - C_3 alkyl,
 - (13) $-CO-O-R_{N-5}$ where R_{N-5} is:
 - (a) C_1 - C_6 alkyl, or
 - (b) $-(CH_2)_{0-2}-(R_1\text{-aryl})$ where $R_1\text{-aryl}$ is as defined above,
 - (14) $-SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,
 - (15) $-SO-(C_1-C_8 \text{ alkyl})$,
 - (16) $-SO_2-(C_3-C_{12} \text{ alkyl})$,
 - (17) $-NH-CO-O-R_{N-5}$ where R_{N-5} is as defined above,
 - (18) $-NH-CO-N(C_1-C_3 \text{ alkyl})_2$,
 - (19) $-N-CS-N(C_1-C_3 \text{ alkyl})_2$,
 - (20) $-N(C_1-C_3 \text{ alkyl})-CO-R_{N-5}$ where R_{N-5} is as defined above,
 - (21) $-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} can be the same or different and are as defined above,
 - (22) $-R_{N-4}$ where R_{N-4} is as defined above,
 - (23) $-O-CO-(C_1-C_6 \text{ alkyl})$,
 - (24) $-O-CO-N(C_1-C_3 \text{ alkyl})_2$,
 - (25) $-O-CS-N(C_1-C_3 \text{ alkyl})_2$,

- (26) -O-(C₁-C₆ alkyl),
 (27) -O-(C₂-C₅ alkyl)-COOH,
 (28) -S-(C₁-C₆ alkyl),
 (29) C₁-C₆ alkyl unsubstituted or substituted with 1,
 2, 3, 4, or 5 -F,
 (30) -O-(C₁-C₆ alkyl unsubstituted or substituted with
 1, 2, 3, 4, or 5 -F, or
 (31) -O- ϕ ;

R_{N-1} is phenyl that is independently substituted with one, two,
 three or four of R₁₀₀;

R_a is hydrogen or C₁-C₆ alkyl;

R_c is

A¹ R_{CH} where R_{CH} is morpholinyl, thiomorpholinyl,
 thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide,
 piperazinyl, homopiperazinyl, pyrrolidinyl,
 pyrrolinyl, tetrahydropyranyl, piperidinyl,
 tetrahydrofuranyl, or tetrahydrothiophenyl, each of
 which is optionally substituted with
 oxo, C₁-C₃ alkyl, -CF₃, -F, Cl, -Br or -I, C₁-C₃
 alkoxy, -O-CF₃, -NH₂, -OH, or -C \equiv N;

#11 B¹
 ZT
 10/6/04
 R_{CH} where R_{CH} is pyridinyl, pyrimidinyl, quinolinyl, indenyl,
 indanyl, benzothiophenyl, indolyl, indolinyl,
 pyridazinyl, pyrazinyl, isoindolyl, isoquinolyl,
 quinazolinyl, quinoxalinyl, ~~thiazolinyl~~, ~~imidazolinyl~~,
 isoxazolyl, pyrazolyl, oxazolyl, thiazolyl,
 indolizinyl, indazolyl, benzothiazolyl,
 benzimidazolyl, benzofuranyl, furanyl, thienyl,
 pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl,
 tetrazolyl, 1, 4-benzodioxanyl, purinyl,
 oxazolopyridinyl, imidazopyridinyl, isothiazolyl,
 naphthyridinyl, cinnolinyl, carbazolyl, β -carbolinyl,

isochromanyl, chromanyl, furazanyl,
tetrahydroisoquinoline, isoindolinyl,
isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl,
isobenzothiophenyl, benzoxazolyl, or pyridopyridinyl,
each of which is optionally substituted with C₁-C₃ alkyl,
-CF₃, -F, Cl, -Br, or I, C₁-C₃ alkoxy, -O-CF₃, -NH₂, -OH,
or -C≡N;
- (C₁-C₁₀)alkyl-R_{CH}; or
- (C₁-C₁₀)alkyl-R_{CY}.

AI
Claim 189 (new) A compound according to claim 172, which
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-
(piperidine-1-carbonyl)-hexyl]-N,N-dipropyl-isophthalamide.

Claim 190 (new) A compound according to claim 172, which
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-(2-
morpholin-4-yl-ethylcarbamoyl)-pentyl]-5-methyl-N,N-dipropyl-
isophthalamide.

Claim 191 (new) A compound according to claim 172, which
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-
[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-pentyl]-5-methyl-N,N-
dipropyl-isophthalamide.

Claim 192 (new) A compound according to claim 172, which
is N-[1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-methyl-5-
morpholin-4-yl-5-oxo-pentyl]-5-methyl-N,N-dipropyl-
isophthalamide.

Claim 193 (new) A compound according to claim 172, which
is N-[1-(S)-(3,5-Difluoro-benzyl)-4-(R)-[(furan-2-ylmethyl)-

carbamoyl]-2-(S)-hydroxy-pentyl)-5-methyl-N,N-dipropyl-isophthalamide.

194. (new) A pharmaceutical composition comprising a compound according to claim 188 in combination with a pharmaceutically acceptable carrier.

195. (new) A method ~~according~~ of treating ~~or preventing~~ Alzheimer's Disease comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 188.
